181.62
前日終値:
$190.02
開ける:
$189.71
24時間の取引高:
401.10K
Relative Volume:
0.53
時価総額:
$3.83B
収益:
$1.77M
当期純損益:
$-123.74M
株価収益率:
-19.81
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+215.78%
1か月 パフォーマンス:
+274.72%
6か月 パフォーマンス:
+403.34%
1年 パフォーマンス:
+150.66%
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PRAX
Praxis Precision Medicines Inc
|
181.86 | 4.00B | 1.77M | -123.74M | -95.21M | -9.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
427.54 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
463.14 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
582.73 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
815.41 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.12 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-02 | 再開されました | Oppenheimer | Outperform |
2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
2025-02-11 | 開始されました | Deutsche Bank | Buy |
2024-08-05 | 開始されました | Oppenheimer | Outperform |
2024-06-24 | 開始されました | Needham | Buy |
2024-06-18 | 開始されました | Guggenheim | Buy |
2024-05-01 | 開始されました | Robert W. Baird | Outperform |
2023-09-19 | 開始されました | Truist | Buy |
2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
2021-12-16 | 開始されました | H.C. Wainwright | Buy |
2021-08-26 | 開始されました | BofA Securities | Buy |
2021-04-26 | 開始されました | William Blair | Outperform |
2020-11-11 | 開始されました | Wedbush | Outperform |
2020-11-10 | 開始されました | Cowen | Outperform |
2020-11-10 | 開始されました | Evercore ISI | Outperform |
2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor - Insider Monkey
Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.Market Movement Recap & Community Driven Trade Alerts - newser.com
Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade
Multi asset correlation models including Praxis Precision Medicines Inc. - newser.com
Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView
12 Reddit Stocks That Will Go to the Moon - Insider Monkey
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Stop Loss & Verified Stock Trade Ideas - newser.com
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Published on: 2025-10-20 08:35:46 - newser.com
Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView
Largest borrow rate increases among liquid names - TipRanks
Published on: 2025-10-20 07:35:45 - newser.com
Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener
Praxis Precision Medicines Announces Underwritten Offering - TradingView
Praxis surges after late-stage trial success for movement disorder therapy - MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesPortfolio Return Summary & Safe Capital Growth Trade Ideas - nchmf.gov.vn
Praxis Precision Medicines (PRAX) Is Up 256.7% After Positive Phase 3 Results for Essential Tremor Drug - simplywall.st
Is Praxis Precision Medicines Inc. stock a buy on dipsJuly 2025 Fed Impact & Verified Stock Trade Ideas - nchmf.gov.vn
Major Investment Alert: Adage Capital’s Bold Move in Praxis Precision Medicines! - TipRanks
Is Praxis Precision Medicines Inc. stock cheap at current valuationJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - nchmf.gov.vn
PRAX underwritten deal: $157/share, warrants; $567M net proceeds - Stock Titan
PRAX prices common stock and pre-funded warrants; proceeds ~$493.0M - Stock Titan
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - FinancialContent
Can Praxis Precision Medicines Keep Climbing? - timothysykes.com
[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity - Stock Titan
Praxis Shares Skyrocket: Too Late to Buy? - StocksToTrade
Praxis Precision Medicines: A New High? - timothysykes.com
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - Benzinga
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - Insider Monkey
Ulixacaltamide Trial Success Propels PRAX - StocksToTrade
Boston biotech raises $525M after stock triples on late-stage drug trial results - The Business Journals
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? - Yahoo Finance
Praxis Precision Medicines (PRAX) Stock Soars After Essential Tremor Drug Success - parameter.io
Praxis Precision Medicines, Inc. (PRAX) Stock: Soars 183% Following $525M Public Offering Announcement - parameter.io
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating - MarketScreener
Praxis Precision Medicines extends rally after $525 mln stock sale - TradingView
Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats (PRAX) - Seeking Alpha
Praxis Precision Medicines Reaches Analyst Target Price - Nasdaq
Praxis Precision Medicines prices $525 million public offering By Investing.com - Investing.com Nigeria
Why Praxis Precision Medicines Stock Skyrocketed - TipRanks
Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win - Stocktwits
Praxis Precision Medicines Prices $525 Million Share Offering - MarketScreener
Praxis Precision Medicines prices $525 million public offering - Investing.com India
Praxis Precision Medicines (PRAX) Aims to Raise $525M Through Pu - GuruFocus
Praxis Precision Medicines prices $525M public offering - MSN
A Look at Praxis Precision Medicines (PRAX) Valuation Following Positive Phase 3 Results in Essential Tremor - simplywall.st
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering - Investing News Network
Praxis Precision Medicines Announces Pricing of $525 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Option Exercise |
56.94 |
7,583 |
431,776 |
18,540 |
Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
大文字化:
|
ボリューム (24 時間):